Abstract. By using a combination of a heterologous antiserum to GPIb/glycocalicin and a radiolabeled monoclonal antibody to GPIb/glycocalicin, we were able to develop a sensitive and specific radioimmunoelectrophoretic assay that can distinguish small amounts of glycocalicin from GPIb. Normal plasmas were found to contain glycocalicin, even in samples treated with protease inhibitors and centrifuged extensively to remove platelets and platelet fragments. Confirmation that the plasma antigen had a relative molecular weight similar or identical to glycocalicin was obtained from studies employing gel chromatography and affinity chromatography. An immunoradiometric assay was developed to quantify plasma glycocalicin, and normal plasma was found to contain -1-3 gg/ml. The plasma of a patient with severe thrombocytopenia due to aplastic anemia had <12.5% of the normal level of glycocalicin, whereas two patients with thrombocytopenia due to diseases of increased platelet destruction (idiopathic thrombocytopenic purpura and hemolytic-uremic syndrome) had normal levels. Thus, there appears to be ongoing catabolism of platelet GPIb in vivo, and we postulate that the plasma level ofglycocalicin reflects a complex function offactors, including platelet count, platelet turnover, and the site of platelet destruction.
Introduction
The platelet membrane glycoprotein designated GPIb (Mr 170,000) is composed of a larger a-chain (Mr 143,000) and a smaller a-chain (Mr 23,000) held together by one or more disulfide bonds (1, 2) . The a-chain has a small hydrophobic portion Receivedfor publication 5 July 1983 and in revisedform 27 October 1983. that is thought to be imbedded in the membrane and a larger, carbohydrate-rich region that extends out from the membrane.
The external (Mr - 135,000) portion of the a-chain has been given the name glycocalicin (3); it is readily cleaved from the intact a-chain by a variety of enzymes (1, 4) , most notably a calcium-dependent, sulfhydryl, neutral protease(s) found in platelets (1, 5, 6) .
Based on our previous studies, which suggest that this protease may be activated during prolonged in vitro platelet aggregation (7), on evidence of selective digestion of GPIb during platelet storage in vitro (8) , and on the possibility that platelets might release this enzyme into the calcium-rich plasma environment during in vivo platelet disintegration, we hypothesized that glycocalicin may circulate in vivo. To test this hypothesis, we used our previously characterized monoclonal antibody that reacts with an epitope on the glycocalicin portion of GPIba (9) , to develop immunoelectrophoretic and immunoradiometric assays for glycocalicin. Our data indicate that glycocalicin does, indeed, circulate in vivo in significant concentrations.
Methods
Plasma samples were prepared from whole blood drawn into either 10 mM sodium EDTA or 13 mM sodium citrate. The blood was sequentially centrifuged for platelet-rich plasma (PRP),' 700 g for 3.5 min at 220C, platelet-poor plasma, 2,000 g for 10 min at 220C, and platelet-free plasma, 20,000 g for 1 hour at 4VC. Some platelet-free plasma was then filtered through a 0.22-Mm filter (Millex-GS, Millipore Corp., Bedford, MA) and centrifuged at 100,000 g for 3 h at 220C. In all cases, plasma was removed carefully with a plastic pipette so as to avoid the topmost layer. All samples were tested immediately or frozen at -200C. In experiments designed to minimize in vitro proteolysis, blood was drawn into a syringe containing 10 mM N-ethylmaleimide (NEM) (Aldrich Chemical Co., Inc., Metuchen, NJ), I mM leupeptin (Sigma Chemical Co., St. Louis, MO), 0.1 MM PGE1 (Upjohn Co., Kalamazoo, MI), and 10 mM EDTA. In some experiments dibucaine (I mM; Sigma Chemical Co.) was added to PRP and incubated at 370C for 3 h before plateletfree plasma was prepared. Polyacrylamide gel electrophoresis and staining of gels were performed as previously described (9) . Silver staining was performed with the reagents from Bio-Rad Laboratories (Richmond, CA). Antibody 6DI (a murine monoclonal antibody that blocks ris-tocetin-induced binding of von Willebrand factor to platelets and reacts with both glycocalicin and GPIb) was prepared and purified as previously described (9) . lodination was achieved with lactoperoxidase as previously described (9) or by chloramine T using tyrosine to stop the reaction. The specific activities of the different preparations ranged from 200 to 900 cpm/ng; >90% of the radioactivity of all preparations used was precipitable with 10%.trichloroacetic acid, and autoradiography of the protein preparations after sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis showed virtually all of the radioactivity to migrate with the intact immunoglobulin.
Immunoelectrophoresis was performed on premade 1.5% agarose gels in 35 mM barbital buffer, pH 8.6 (Immunoelectrofilm, Kallestad Laboratories, Inc., Chaska, MN). The running buffer contained 27 mM barbital, 23 mM sodium acetate, and 15 mM sodium azide. Samples (3 Ml) were electrophoresed at 100 V at 220C until the bromophenol blue tracking dye placed in a well containing normal serum migrated to the 32-mm mark (-60-100 min). After electrophoresis, troughs were filled with 100 Al ofthe purified heterologous anti-glycocalicin antibody, (4.2 mg/ml) to which sufficient I251-6D1 antibody was added to obtain between 50,000 and 140,000 cpm; diffusion was allowed to proceed overnight. After extensive washing in saline and a water rinse, the gels were dried and radioautography was performed with x-ray film (XAR-5, Eastman Kodak Co., Rochester, NY) until the bands were visible (2 d-3 wk). In some experiments, the gels were stained for 5 min with 0.05% amido black before radioautography.
Washing and Triton X-100 solubilization of platelets for immunoelectrophoresis from citrated PRP ('/,oo vol of 40% trisodium citrate) was performed as described by Nurden et al. (10) , except that the final centrifugation was at 22°C. To estimate the quantity of glycocalicin in normal plasma, immunoelectrophoresis was performed on dilutions of a 3-M KCI extract (see below) of washed platelets resuspended to the same count as the original PRP (7 X 108/ml), and on the platelet-free plasma from the same sample. The platelet pellet remaining after KC1 extraction was solubilized in SDS and subjected to polyacrylamide gel electrophoresis; periodic acid-Schiff (PAS) staining confirmed that the extraction procedure was nearly complete, since only traces of GPIb remained.
Glycocalicin and GPIb purification. As glycocalicin is released from platelets incubated with 3 M KCI (4), presumably as a result ofactivation of the calcium-dependent protease(s) (1, 5, 6) , outdated platelet concentrates were so treated as the first step in glycocalicin purification. This solubilized material was further purified by two methods: first, a modification of the technique of Solum et al. (4) previously reported (9) , which employed a column of wheat germ agglutinin; and second, affinity chromatography on a column of 6D1 antibody, elution being achieved with 0.05 M diethylamine, 10 mM EDTA, 0.05% Triton X-100, and 0.05% NaN3, pH 11.5. With both purification techniques, polyacrylamide gel electrophoresis of both nonreduced and reduced samples revealed a single major PAS-positive band of 130,000 M,; usually no bands or only minor bands were visible when the same gel was stained with Coomassie Blue, but bands corresponding to the PASpositive bands were seen with silver staining. Heterologous antiserum was prepared in a New Zealand white female rabbit by intradermal injections of -50 Ag glycocalicin in complete Freund's adjuvant on day 1, -25 Mg glycocalicin in incomplete Freund's adjuvant on day 13, and -25 g glycocalicin in buffer on day 21. 2 wk after the last injection, the animal was sacrificed and 130 ml of blood was obtained. The antiserum gave multiple precipitin arcs against normal plasma in immunoelectrophoresis, but only a single arc against lysed platelets. To remove contaminating antibodies, 45 ml of antisera was precipitated with 50% ammonium sulfate, resuspended in 14 ml of 10 mM sodium phosphate buffer, pH 8, and absorbed with 2.1 ml normal plasma. The IgG fraction (4.4 mg/ml) was obtained by DEAE-cellulose (DE-52, Whatman Chemical Separation Inc., Clifton, NJ) chromatography and dialyzed against 0.15 M NaCl, 10 mM sodium phosphate, and 0.1% sodium azide, pH 7.4; it gave no visible precipitin arcs with normal plasma or serum.
Partial purification of GPIb was performed on an affinity column containing 10 mg of 6DI antibody coupled to 6 ml of Affigel-O0 (BioRad Laboratories). Platelet concentrates (10 U) that were outdated, but <40-h-old, were pooled, made 10 mM in EDTA, washed three times in 96.5 mM NaCI, 85.7 mM glucose, 8.5 mM Tris/Cl, 10 mM EDTA, pH 7.4, and lysed in 0.15 M NaCl, 10 mM Tris/Cl, 20 mM EDTA, 20 mM NEM, 0.05% NaN3, 1% Triton X-100, pH 7.4, by sonication and rocking at 4VC for 1.5 h. After centrifuging the sample at 12,000 g for 15 min at 4VC and recentrifuging the supernatant at 100,000 g for 90 min at 4°C, the solubilized platelets were applied to the 6D1 column. The column was washed sequentially with (a) 0.15 M NaCl, 0.01 M Tris/Cl, 10 mM EDTA, and 1% Triton X-100, pH 7.4; (b) 0.15 M NaCl, 0.01 M Tris/Cl, 10 mM EDTA, 0.05% Triton X-100, and 0.05% sodium azide, pH 7.4; and (c) 1.5 M NaCl, 0.05% Triton X-100, and 10 mM EDTA, pH 7.4. GPIb was eluted with 0.05 M diethylamine, 10 mM EDTA, and 0.05% Triton X-100, pH 11.5. The peak tubes were pooled, dialyzed against the second wash buffer indicated above, and frozen at -20°C. When a nonreduced, SDS sample of the preparation was electrophoresed in a 7% polyacrylamide gel and stained with PAS, a major band of Mr 155,000, corresponding to GPIb, and a minor band of Mr 125,000, corresponding to glycocalicin, were seen. Silver staining also showed these two bands with only minor contaminants, while Coomassie Blue failed to stain the PAS-positive bands, but did reveal minor contamination with several proteins of lower relative molecular weight.
Upon reduction, a single major PAS-positive band was seen at Mr 130,000, and a weak band appeared at Mr 23,000. In both nonreduced and reduced samples, a weak PAS-positive band was seen at or near the dye front, which may correspond to the M, 20,000 protein that we previously found to copurify with GPIb (9) .
Immunoradiometric assay. To quantify 6Dl-reactive antigen in plasma, an immunoradiometric assay was adapted from the enzymelinked immunosorbent assay described by Michelson et al. (11) . It is based on the principle that 6D1 antibody that reacts with plasma antigen will subsequently be unable to bind to GPIb on platelets. In brief, 25-Ml samples of citrated PRP (2 X 108 platelets/ml) or platelet-free plasma (control) were added to an appropriate number of wells of a 96-well microtiter plate, the bottoms of which consisted of 0.22-Mm filters (GV milliliter plate, Millipore Corp.). After a few seconds to permit spreading, the plasma was drawn through the membranes by vacuum with a manifold (Millipore Corp.) and the immobilized platelets were washed twice with 200 Ml of phosphate buffer containing albumin (0.15 M NaCl, 0.01 M sodium phosphate, 1% bovine serum albumin, and 0.05% NaN3). In a separate round-bottomed, plastic microtiter plate, 200 Ml of plasma or dilutions of plasma made in the above buffer were incubated with 5 MI of '25I-6D1 antibody containing 6-15 X 103 cpm for 20 min at 21 'C.
This mixture was then added to the wells containing platelets and allowed to incubate an additional 3 h at 21 'C with gentle rotation (Tektator V, American Scientific Products, McGaw Park, IL). Each well was then dried by vacuum, washed five times with 100 Ml of the above buffer, and five times with 100 Ml of the above buffer in which 0.05% Tween 20 (Sigma Chemical Co.) was substituted for the albumin. After a final vacuum drying, the membranes were punched out from the bottom of the wells and counted in a gamma counter. Data were analyzed by subtracting the cpm of membranes coated with platelet-free plasma (control) from those to which platelets were attached, and then plotting the results of the net cpm bound as a function of the plasma dilution (neat to '/32) on log-log paper (Fig. 1) . A straight line was usually obtained for the dilutions ranging from neat to l/8 or 1/16 When eight replicates were performed at each dilution, the coefficients of variation averaged 7.95% (Fig. 1) .
Gel chromatography ofplasma and KCl extract. To obtain an indication ofthe molecular size ofthe immunoreactive material in plasma and to compare it with glycocalicin in KCI extracts, both plasma (3 ml) and a KCI extract (3 ml of a 1/I0 dilution prepared in column buffer, OD28o = 0.093) were chromatographed on a 69 X 1.25-cm column of Sephacryl S-300 (Pharmacia Fine Chemicals, Piscataway, NJ). The plasma was obtained by centrifuging whole blood drawn into a syringe containing 10 mM EDTA, 10 mM NEM, I mM leupeptin, and 0.1 m PGE1 at 3,000 g for 20 min at 4VC and then at 100,000 g for I h at 4VC. Elution was carried out at 4VC with a buffer of 0.2 M NaCl, 0.01 M Tris/Cl, 2 mM EDTA, and 0.05% sodium azide, pH 7.4, at a rate The last buffer eluted a protein peak that was then dialyzed against the initial wash buffer and subjected to polyacrylamide gel electrophoresis and chromatography on the Sephacryl S-300 column. Radioimmunoelectrophoresis. Fresh, washed platelets that were solubilized in Triton X-100 gave a single broad radioactive arc that began at the sample application well, increased in intensity more anodally, and ended at a location that corresponded to the middle of the albumin peak seen in serum samples run in neighboring wells (Fig. 2 A) . Purified GPIb gave a very similar arc (along with a minor, more anodal arc corresponding to the small amount ofcontaminating glycocalicin; see below). In contrast, the 3-M KCI extract ofplatelets gave a narrower radioactive arc with a more anodal migration, beginning at a position near the end of the GPIb arc and extending to a position near the end of the corresponding albumin peak. Purified glycocalicin gave a similar arc (along with a minor, less anodal arc corresponding to where a glycocalicin proteolysis product migrates; data not shown).
Plasma samples from eight normal donors all revealed radioactive arcs corresponding in location to those given by the 3-M KCl extract and the purified glycocalicin. No arcs corresponding in location to those given by solubilized platelets or purified GPIb were identified. There were no qualitative differences between blood drawn into citrate, EDTA, or EDTA, NEM, PGEI, and leupeptin. Moreover, there were no differences between blood centrifuged at 2,000 g for 10 min and blood that was both centrifuged for longer times at greater centrifugal force (including 100,000 g for 3 h) and passed through a 0.22-am filter. In fact, uncentrifuged PRP did not give a more intense glycocalicin arc than platelet-free plasma; the PRP sample did, however, show increased radioactivity associated with the application well. In contrast, the plasma from a patient with severe aplastic anemia and a platelet count of 6,000/h gave only the faintest hint ofa glycocalicin precipitin arc, even with prolonged exposure (lane 5, Fig. 2 A) .
The glycocalicin arc was enhanced in plasma prepared from citrated PRP that was either treated with dibucaine, a local anesthetic known to cause the digestion of GPIb (7), or subjected to freezing and thawing three times before being centrifuged at 20,000 g for 60 min at 4VC (Fig. 2 B) . The study comparing the glycocalicin content of platelet-free plasma and a 3-M KC1 extract of the platelets from the same PRP sample showed that the platelet-free plasma glycocalicin arc was more intense than the 1/4 dilution of the 3-M KCI extract, but less intense than the l/2 dilution. We therefore estimated it at -1/3, which would be equivalent to the glycocalicin that could be extracted from -2.33 X 108 platelets/ml. If one estimates that there are -26,000 GPIb sites per platelet (9) , these data suggest that the glycocalicin content of plasma is -I0 nM or -1.5 ,ug/ml.
Immunoradiometric assay. Preliminary studies showed that the plasmas from all normals tested contained antigen identifiable by the assay, even when the plasma was prepared from whole blood collected into a syringe containing 10 mM EDTA, 10 mM NEM, 1 mM leupeptin, and 0.1 uM PGE, by centrifugation at 100,000 g for 2 h. In fact, plasma prepared by drawing blood into a syringe containing 10 mM EDTA and centrifuging thrice at 12,000 g for 5 min at 22°C gave identical results to those obtained with the combination indicated above. A pool of plasmas obtained from 19 separate individuals was prepared from blood anticoagulated with 10 mM EDTA and centrifuged thrice (3,000 g for 20 min, 20,000 g for 10 min, and 20,000 g for 10 min, all at 4°C). The pool was frozen at -20°C and used as the standard for each ofthe assays. 13 of the plasmas making up the pool were assayed separately and found to contain 99±34% (mean±SD; range 52-156%) ofthe pool value. Dilution curves of individual members of the pool were parallel to that of the pool itself. The glycocalicin antigen content of the pool of normal plasma was quantified by comparison with both a KC1 extract of 5 X 109 platelets/ml and with a purified preparation ofGPIb/glycocalicin that contained 128 jg/ml of protein by an assay according to Lowry. The pool contained 1.2 pg/ml of glycocalicin antigen when judged against the former and 3 ,ug/ml when judged against the latter. Both are in good agreement with the value (1.5 gg/ml) estimated from the immunoelectrophoresis experiment. In contrast to normal plasma, the plasma from a patient with aplastic anemia and a platelet count of 6,000/4d did not contain enough antigen to be assayed in the linear portion of the assay curve (<12.5%). Estimation of the amount of antigen present from the nonlinear portion of the curve ranged from 3.5 to 11% of normal. Plasma obtained from a 12-yr-old male with acute idiopathic thrombocytopenic purpura and a platelet count of 3,000/M1 contained 68% of normal, and that of a 6-yr-old male with hemolytic-uremic syndrome (microangiopathic hemolytic anemia and azotemia) with a platelet count of 25,000/Ml contained 128% of normal. Thus, the plasma glycocalicin level is not simply a reflection of the peripheral platelet count.
Gel chromatography ofplasma and KCl extract. The KCl extract contained very little material that absorbed at 280 nM (Fig. 3) . Material rich in immunoreactivity eluted well after the void volume, with peak elution at 70 ml. Plasma gave a characteristic 280-nm absorption pattern with three peaks corresponding to IgM, IgG, and albumin as judged by polyacrylamide gel electrophoresis. Immunoreactive material eluted between the IgM and IgG peaks and peak elution occurred at 70 ml, coinciding precisely with the peak found with the KC1 extract. The shape of the peak differed slightly from that of the KC1 extract, but the shift, if any, was less than a single tube. The total amount of antigen recovered from the plasma peak represented more than 70% of that applied. The peak tubes were tested in the immunoelectrophoresis system and found to be positive, with arcs corresponding to the position ofglycocalicin.
6D1 affinity chromatography ofplasma. The PAS stain of the nonreduced polyacrylamide gel of the material eluted by diethylamine showed a major band ofMr -125,000, along with a diffuse band at M, 80-88,000 (Fig. 4, lane A) . Upon reduction, the Mr 125,000 band remained essentially unchanged, whereas the Mr -85,000 decreased in intensity and a new band of M, 40 ,000 appeared (lane B). The Mr 125,000 band corresponds in migration to the glycocalicin found in a 3-M KCI extract (lane C), which had the same migration nonreduced and reduced. As is characteristic of glycocalicin, Coomassie Blue staining of the same gels revealed that all the Mr 125,000 bands were associated with only weakly staining protein bands. In contrast, the Mr 80-88,000 bands on both the nonreduced and reduced gels and the Mr 40,000 band on the reduced gel corresponded to intensely staining protein bands (data not shown). The Coomassie Blue stain also showed significant amounts of IgG, as judged by the characteristic changes in relative molecular weight with reduction. When the eluted material was chromatographed on the Sephacryl S-300 column, the immunoreactive material eluted with a single peak that corresponded in location to that from the KC1 extract.
Discussion
The cleavage ofglycocalicin from GPIb by a variety of proteases, including one or more calcium-dependent proteases from plate- lets, has been demonstrated by several different groups (1, 4, 6, 7) . If such a calcium-dependent enzyme were to be released from disintegrating platelets into the calcium-rich plasma milieu, it could act either on GPIb extending out from the platelet surface or, ifGPIb were involved in adhesion, on GPIb molecules attached simultaneously to the subendothelium and the platelet. In the former case, glycocalicin would be set free into the circulation, while in the latter case, the platelet could be set free from the surface to reenter the circulation. In vitro analogues of such a process may include prolonged incubation of platelet concentrates at room temperature (8) , activation ofthe calciumdependent enzyme(s) by local anesthetics (7) , and the reversibility of von Willebrand factor-dependent platelet agglutination with Figure 3 . Elution profiles of protein (absorbance at 280 nm) and 6DI-reactive antigen from a column of Sephacryl S-300. 3-ml samples of a KCl extract of platelets (A) and normal platelet-free plasma (B) were chromatographed on a 69 X 1.25-cm column at 2 ml/h. Elution was with 0.2 M NaCl, 0.01 M Tris/CI, 2 mM EDTA, 0.05% sodium azide, pH 7.4, and 2-ml fractions were collected. The void volume of the column is indicated.
prolonged incubation (7); in each case, available evidence supports the proposed model. Previous in vivo studies by George et al. in rabbits indicated that there is loss of platelet membrane glycoproteins with aging, although they did not find selective loss of GPIb (12) .
The current study employed our monoclonal antibody (6D1) that blocks ristocetin-induced binding of von Willebrand factor to platelets and reacts with both glycocalicin and GPIb (9) . By exploiting the known differences in electrophoretic mobility of glycocalicin and GPIb (4), we designed a system in which a heterologous anti-glycocalicin immunoglobulin fraction (used to precipitate any GPIb or glycocalicin) and radiolabeled 6D1 (which is nonprecipitating) are used in concert to achieve both high sensitivity and specificity in detecting GPIb and glycocalicin. Quantitation was achieved with an immunoradiometric assay and normal plasma was found to contain 1-3 ,gg/ml. Gel chromatography and affinity chromatography were used to confirm that the plasma antigen had a relative molecular weight similar to that of glycocalicin.
Glycocalicin was consistently identified in plasmas from normal individuals. It is unlikely that the glycocalicin identified resulted from the presence of residual platelets, since (a) centrifugation at forces in excess of those needed to sediment both platelets and the recently described platelet membrane microparticles (13) did not reduce the amount of glycocalicin; (b) purposeful contamination of plasma with platelets did not produce an enhanced glycocalicin arc in immunoelectrophoresis, and (c) patients with some diseases causing profound thrombocytopenia had normal levels of plasma glycocalicin. We also took measures to minimize in vitro proteolysis by drawing the blood directly into PGE1 and agents known to inhibit proteolysis ofGPIb (4, 7, 14) ; again, there were no differences in the observed arcs. On the other hand, dibucaine treatment and freezing and thawing platelets are known to decrease platelet GPIb, and they were associated with increased glycocalicin in the plasma.
Plasma from a patient with severe thrombocytopenia due to aplastic anemia had virtually no detectable glycocalicin, suggesting that plasma glycocalicin is derived from the catabolism of platelet GPIb. The patient with acute idiopathic thrombocytopenic purpura had a platelet count k/5o that of normal and a glycocalicin level in the low normal range, and the patient with hemolytic-uremic syndrome had a platelet count 'Ao that of normal and a glycocalicin level in the high normal range. Thus, the glycocalicin level does not seem to be simply a reflection of the peripheral platelet count. Our preliminary data lead us to suspect that plasma glycocalicin levels reflect a complex function of platelet mass, platelet turnover, and perhaps, the site of destruction (intravascular or extravascular); differences in glycocalicin clearance may also affect the level. Extensive clinical studies will be required to define these relationships. Finally, while we believe that it is reasonable to hypothesize that the platelet-derived, calcium-dependent protease is responsible for the proteolysis of platelet GPIb, we wish to stress that the current studies do not directly address the identity of the in vivo protease(s).
